Skip to main content
Loading

50 years of monoclonals - lead identification and optimization in the times of AI/ML, multispecific formats and ADCs.

01 Dec 2025
Lead Identification & Optimization
  • Can AI/ML really help to speed up antibody discovery (already)? How far can we get without a lab?
  • What are the requirements of leads for multispecific formats and ADCs? Are they identical to "naked" antibodies?
  • Is it still Fab and IgG? What are the best building blocks for next generation therapeutics?
  • Is it still all about affinity? What to optimize for next generation therapeutics?
Industry Expert
Jürgen Klattig, Director Antibody Discovery & Protein Interactions - iOmx Therapeutics AG